{"id":"W2805086678","doi":"10.1016/j.eururo.2018.05.005","title":"Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II)","year":2018,"lang":"en","type":"article","venue":"European Urology","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Health Sciences Centre","funders":"Astellas Pharma Europe; Astellas Pharma","keywords":"Mirabegron; Solifenacin; Medicine; Overactive bladder; Urology; Safety profile; Tolterodine; Combination therapy; Extended release; Internal medicine; Adverse effect; Pharmacology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005334735,0.001582091,0.004148487,0.000617261,0.0004909196,0.001201122,0.001016774,0.001722442,0.004419605],"category_scores_gemma":[0.002936554,0.00101152,0.004196274,0.0006822919,0.001357981,0.001350427,0.0007530075,0.00307264,0.0007521169],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001073882,"about_ca_system_score_gemma":0.001870359,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005680892,"about_ca_topic_score_gemma":0.001557244,"domain_scores_codex":[0.9977233,0.001335372,0.0002199925,0.0002994784,0.0002194255,0.000202362],"domain_scores_gemma":[0.9973415,0.0006072824,0.001082308,0.0001920787,0.000148659,0.0006282614],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9757229,0.007342363,0.001789305,0.0005406051,0.001542992,0.00002980177,0.00007100138,0.0002513605,0.003091809,0.00002864691,0.0002536152,0.009335578],"study_design_scores_gemma":[0.7793031,0.2144426,0.004483542,0.00003569805,0.0007508484,0.000044819,0.00002551465,0.0002327088,0.0003657175,0.00005237324,0.0002437579,0.00001940475],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919865,0.004046046,0.0004045226,0.0002902734,0.0001498506,0.002054552,0.0005004504,0.0000397993,0.0005280472],"genre_scores_gemma":[0.9916979,0.001729401,0.001504791,0.0005836908,0.0003192401,0.002896232,0.0006377414,0.00001370538,0.0006173977],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005334735,"threshold_uncertainty_score":0.02821308,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01219313888682709,"score_gpt":0.2894866163821063,"score_spread":0.2772934774952792,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}